Exelixis is Expanding Cohorts for COSMIC-021, the Phase 1b Trial for Cabozantinib
From Exelixis (EXEL) we learned about its decision to expand the two original cohorts, and the addition of four new cohorts, to the protocol for COSMIC-021; the phase 1b trial of cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) in patients with locally advanced or . . .
This content is for paid subscribers.
Today’s Highlights July 15, 2019